Voices
Molecular Classification
Vivek Subbiah, Benedikt Westphalen, Giuseppe Curigliano, Fabrice Andre

Vivek Subbiah: We Advocate for a Forward Thinking Molecular Classification to Bridge Diagnosis and Treatment

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:

” Bridging tumour classification and treatment – The Lancet Oncology. We advocate for a forward thinking molecular classification to bridge diagnosis & treatment.”

Title: Bridging tumour classification and treatment

Authors: Vivek Subbiah, Benedikt Westphalen, Giuseppe Curigliano, Fabrice Andre

Read Full Article.

Molecular Classification

More posts featuring Vivek Subbiah on OncoDaily.

Benedikt Westphalen cancer Fabrice Andre Giuseppe Curigliano OncoDaily Oncology The Lancet The Lancet Oncology tumour classification and treatment Vivek Subbiah